Elevated Serum Inflammatory Markers in Subacute Stroke Are Associated With Clinical Outcome but Not Modified by Aerobic Fitness Training: Results of the Randomized Controlled PHYS-STROKE Trial

Bernadette Kirzinger, Andrea Stroux, Torsten Rackoll, Matthias Endres, Agnes Flöel, Martin Ebinger, Alexander Heinrich Nave, Bernadette Kirzinger, Andrea Stroux, Torsten Rackoll, Matthias Endres, Agnes Flöel, Martin Ebinger, Alexander Heinrich Nave

Abstract

Background: Inflammatory markers, such as C-reactive Protein (CRP), Interleukin-6 (IL-6), tumor necrosis factor (TNF)-alpha and fibrinogen, are upregulated following acute stroke. Studies have shown associations of these biomarkers with increased mortality, recurrent vascular risk, and poor functional outcome. It is suggested that physical fitness training may play a role in decreasing long-term inflammatory activity and supports tissue recovery. Aim: We investigated the dynamics of selected inflammatory markers in the subacute phase following stroke and determined if fluctuations are associated with functional recovery up to 6 months. Further, we examined whether exposure to aerobic physical fitness training in the subacute phase influenced serum inflammatory markers over time. Methods: This is an exploratory analysis of patients enrolled in the multicenter randomized-controlled PHYS-STROKE trial. Patients within 45 days of stroke onset were randomized to receive either four weeks of aerobic physical fitness training or relaxation sessions. Generalized estimating equation models were used to investigate the dynamics of inflammatory markers and the associations of exposure to fitness training with serum inflammatory markers over time. Multiple logistic regression models were used to explore associations between inflammatory marker levels at baseline and three months after stroke and outcome at 3- or 6-months. Results: Irrespective of the intervention group, high sensitive CRP (hs-CRP), IL-6, and fibrinogen (but not TNF-alpha) were significantly lower at follow-up visits when compared to baseline (p all ≤ 0.01). In our cohort, exposure to aerobic physical fitness training did not influence levels of inflammatory markers over time. In multivariate logistic regression analyses, increased baseline IL-6 and fibrinogen levels were inversely associated with worse outcome at 3 and 6 months. Increased levels of hs-CRP at 3 months after stroke were associated with impaired outcome at 6 months. We found no independent associations of TNF-alpha levels with investigated outcome parameters. Conclusion: Serum markers of inflammation were elevated after stroke and decreased within 6 months. In our cohort, exposure to aerobic physical fitness training did not modify the dynamics of inflammatory markers over time. Elevated IL-6 and fibrinogen levels in early subacute stroke were associated with worse outcome up to 6-months after stroke. Clinical Trial Registration:ClinicalTrials.gov, NCT01953549.

Keywords: IL-6; TNF-alpha; biomarkers; crp; fibrinogen; inflammation; outcome; stroke.

Conflict of interest statement

MEn reports grants from Bayer and fees paid to the Charité from AstraZeneca, Bayer, Boehringer Ingelheim, BMS, Daiichi Sankyo, Amgen, GSK, Sanofi, Covidien, Novartis, Pfizer, all outside the submitted work. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Kirzinger, Stroux, Rackoll, Endres, Flöel, Ebinger and Nave.

Figures

Figure 1
Figure 1
Dynamics of inflammatory biomarkers in the PHYS-Stroke study cohort; hs-CRP (A), IL-6 (B), TNF-alpha (C), fibrinogen (D). Levels of markers are expressed as means, 95% CIs as error bars; horizontal dashed lines depict cut-off for normal ranges.
Figure 2
Figure 2
MANOVA-Models, Dynamics of inflammatory biomarkers separated into the two treatment groups; hs-CRP (A), IL-6 (B), TNF-alpha (C), fibrinogen (D); Levels of markers are expressed as Estimated Marginal Means, 95% CIs as error bars; horizontal dashed lines depict cut-off for normal ranges.

References

    1. Whiteley W, Jackson C, Lewis S, Lowe G, Rumley A, Sandercock P, et al. . Inflammatory markers and poor outcome after stroke : a prospective cohort study and systematic review of interleukin-6. PLoS Med. (2009) 6. 10.1371/journal.pmed.1000145
    1. Esenwa CC, Elkind MS. Inflammatory risk factors, biomarkers and associated therapy in ischaemic stroke. Nat Publ Gr. (2016) 12:594–604. 10.1038/nrneurol.2016.125
    1. Liuzzo G, Biasucci LM, Gallimore R, Grillo RL, Rebuzzi AG, Pepys MB, et al. . The prognostic value of c-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med. (1994) 331:417–24. 10.1056/NEJM199408183310701
    1. Ridker PM, Cushman M, Stampfer MJ, Tracy R, Hennekens CH. Inflammation, Aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. (1997) 336:973–9. 10.1056/NEJM199704033361401
    1. Bonaventura A, Liberale L, Vecchié A, Casula M, Carbone F, Dallegri F, et al. . Update on inflammatory biomarkers and treatments in ischemic stroke. Int J Mol Sci. (2016) 1967:1–53. 10.3390/ijms17121967
    1. Elkind MS V, Coates K, Tai W, Paik MC, Boden-albala B, Sacco RL. Levels of acute phase proteins remain stable after ischemic stroke. BMC Neurol. (2006) 6. 10.1186/1471-2377-6-37
    1. Tamam Y, Iltumur K, Apak I. Assessment of acute phase proteins in acute ischemic stroke. Tohoku J Exp Med. (2005) 206:91–8. 10.1620/tjem.206.91
    1. Idicula TT, Brogger J, Naess H, Waje-Andreassen U, Thomassen L. Admission C - reactive protein after acute ischemic stroke is associated with stroke severity and mortality: the “bergen stroke study.” BMC Neurol. (2009) 9:1–9. 10.1186/1471-2377-9-18
    1. Beamer NB, Coull BM, Clark WM, Briley DP, Wynn M, Sexton G. Persistent inflammatory response in stroke survivors. Neurology. (1998) 50:1722–8. 10.1212/WNL.50.6.1722
    1. Marquardt L, Ruf A, Mansmann U, Winter R, Buggle F, Kallenberg K, et al. . Inflammatory response after acute ischemic stroke. J Neurol Sci. (2005) 236:65–71. 10.1016/j.jns.2005.05.006
    1. Welsh P, Lowe GDO, Chalmers J, Campbell DJ, Rumley A, Neal BC, et al. . Associations of proinflammatory cytokines with the risk of recurrent stroke. Stroke. (2008) 39:2226–30. 10.1161/STROKEAHA.107.504498
    1. Li J, Zhao X, Mend X, Lin J, Liu L, Wang C, et al. . High-sensitive C-reactive protein predicts recurrent stroke and poor functional outcome. Stroke. (2016) 2030:2025–30. 10.1161/STROKEAHA.116.012901
    1. Bustamante A, Sobrino T, Giralt D, García-Berrocoso T, Llombart V, Ugarriza I, et al. . Prognostic value of blood interleukin-6 in the prediction of functional outcome after stroke: a systematic review and meta-analysis. J Neuroimmunol. (2014) 274:215–24. 10.1016/j.jneuroim.2014.07.015
    1. Whiteley W, Wardlaw J, Dennis M, Lowe G, Rumley A, Sattar N, et al. . The use of blood biomarkers to predict poor outcome after acute transient ischemic attack or ischemic stroke. Stroke. (2011) 43:86–91. 10.1161/STROKEAHA.111.634089
    1. Dieplinger B, Bocksrucker C, Egger M, Eggers C, Haltmayer M. Prognostic value of inflammatory and cardiovascular biomarkers for prediction of 90-day all-cause mortality after acute ischemic stroke — results from the linz stroke unit study. Clin Chem. (2017) 63:1101–9. 10.1373/clinchem.2016.269969
    1. Hankey GJ. Stroke. Lancet. (2017) 389:641–54. 10.1016/S0140-6736(16)30962-X
    1. Gertz K, Baldinger T, Werner C, Kronenberg G, Ka RE, Miller KR, et al. . Essential role of interleukin-6 in post-stroke angiogenesis. Brain. (2012) 135:1964–80. 10.1093/brain/aws075
    1. Simats A, García-Berrocoso T, Montaner J. Neuroinflammatory biomarkers: from stroke diagnosis and prognosis to therapy. Biochim Biophys Acta Mol Basis Dis. (2016) 1862:411–24. 10.1016/j.bbadis.2015.10.025
    1. Anrather J, Iadecola C. Inflammation and stroke : an overview. Neurotherapeutics. (2016) 13:661–70. 10.1007/s13311-016-0483-x
    1. Chen Y, Apostolakis S, Lip GYH. Exercise-induced changes in inflammatory processes : implications for thrombogenesis in cardiovascular disease. Ann Med. (2014) 46:439–55. 10.3109/07853890.2014.927713
    1. Nave AH, Rackoll T, Grittner U, Bläsing H, Gorsler A, Nabavi DG, et al. . Physical fitness training in patients with subacute stroke (PHYS-STROKE): multicentre, randomised controlled, endpoint blinded trial. BMJ. (2019) 366. 10.1136/bmj.l5101
    1. Flöel A, Werner C, Grittner U, Hesse S, Jöbges M, Knauss J, et al. . Physical fitness training in subacute stroke (PHYS-STROKE) - study protocol for a randomised controlled trial. Trials. (2014) 15. 10.1186/1745-6215-15-45
    1. Mahoney FI, Barthel DW. Functional evaluation: the barthel index. Md State Med J. (1965) 14:61–5.
    1. Nave AH, Kröber JM, Brunecker P, Fiebach JB, List J, Grittner U, et al. . Biomarkers and perfusion - training-induced changes after stroke (BAPTISe): protocol of an observational study accompanying a randomized controlled trial. BMC Neurol. (2013) 13. 10.1186/1471-2377-13-197
    1. Bamford JM, Sandercock PAG, Wariow CP, Slattery J. Interobserver agreement for the assessment of handicap in stroke patients: to the editor. Stroke. (1989) 20:828.
    1. Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika. (1986) 73:13–22.
    1. Whiteley W, Jackson C, Lewis S, Lowe G, Rumley A, Sandercock P, et al. . Association of circulating inflammatory markers with recurrent vascular events after stroke. Stroke. (2010) 42:10–6. 10.1161/STROKEAHA.110.588954
    1. Matsuo R, Ago T, Hata J, Wakisaka Y, Kuroda J, Kuwashiro T, et al. . Plasma C-reactive protein and clinical outcomes after acute ischemic stroke?: a prospective observational study. PLoS ONE. (2016) 11:e0156790. 10.1371/journal.pone.0156790
    1. Warusevitane A, Karunatilake D, Sim J, Smith C, Roffe C. Early diagnosis of pneumonia in severe stroke: clinical features and the diagnostic role of C-reactive protein. PLoS ONE. (2016) 11:e0150269. 10.1371/journal.pone.0150269
    1. Smith CJ, Emsley HCA, Gavin CM, Georgiou RF, Vail A, Barberan EM, et al. . Peak plasma interleukin-6 and other peripheral markers of inflammation in the first week of ischaemic stroke correlate with brain infarct volume, stroke severity and long-term outcome. BMC Neurol. (2004) 4:2. 10.1186/1471-2377-4-2
    1. Nakase T, Yamazaki T, Ogura N, Suzuki A, Nagata K. The impact of inflammation on the pathogenesis and prognosis of ischemic stroke. J Neurol Sci. (2008) 271:104–9. 10.1016/j.jns.2008.03.020
    1. Mengel A, Ulm L, Hotter B, Harms H, Piper SK, Grittner U, et al. . Biomarkers of immune capacity, infection and inflammation are associated with poor outcome and mortality after stroke - The PREDICT study. BMC Neurol. (2019) 19:148. 10.1186/s12883-019-1375-6
    1. Koenig W. Fibrin (ogen) in cardiovascular disease?: an update. Thromb Haemost. (2003) 89:601–9. 10.1055/s-0037-1613566
    1. Altes P, Perez P, Esteban C, Sánchez Muñoz-Torrero JF, Aguilar E, García-Díaz AM, et al. . Raised fibrinogen levels and outcome in outpatients with peripheral artery disease. Angiology. (2018) 69:507–12. 10.1177/0003319717739720
    1. Collaboration FS. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality. JAMA. (2005) 294:1799–810. 10.1001/jama.294.14.1799
    1. Ma J, Hennekens CH, Ridker PM, Stampfer MJ. A prospective study of fibrinogen and risk of myocardial infarction in the Physicians' Health Study. J Am Coll Cardiol [Internet]. (1999) 33:1347–52. 10.1016/S0735-1097(99)00007-8
    1. Welsh P, Barber M, Langhorne P, Rumley A, Lowe GDO, Stott DJ. Associations of inflammatory and haemostatic biomarkers with poor outcome in acute ischaemic stroke. Cerebrovasc Dis. (2009) 27:247–53. 10.1159/000196823
    1. Swarowska M, Ferens A, Pera J, Slowik A, Dziedzic T. Can Prediction of functional outcome after stroke be improved by adding fibrinogen to prognostic model? J Stroke Cerebrovasc Dis. (2016) 25:2752–5. 10.1016/j.jstrokecerebrovasdis.2016.07.029
    1. Del Zoppo GJ, Levy DE, Wasiewski WW, Pancioli AM, Demchuk AM, Trammel J, et al. . Hyperfibrinogenemia and functional outcome from acute ischemic stroke. Stroke. (2009) 40:1687–91. 10.1161/STROKEAHA.108.527804
    1. Zaremba J, Losy J. Early TNF-a levels correlate with ischaemic stroke severity. Acta Neurol Scand. (2001) 104:288–95. 10.1034/j.1600-0404.2001.00053.x
    1. Vila N, Castillo J, Davalos A, Chamorro A. Proinflammatory cytokines and early neurological worsening in ischemic stroke. Stroke. (2000) 31:2325–9. 10.1161/01.STR.31.10.2325
    1. Allen J, Sun Y, Woods JA. Exercise and the regulation of inflammatory responses. In: Progress in Molecular Biology and Translational Science. 1st ed. Vol. 135. Elsevier Inc. (2015). p. 337–54.
    1. Beavers KM, Brinkley TE, Nicklas BJ. Effect of exercise training on chronic inflammation. Clin Chim Acta. (2010) 411:785–93. 10.1016/j.cca.2010.02.069
    1. Sallam N, Laher I. Exercise modulates oxidative stress and inflammation in aging and cardiovascular diseases. Oxid Med Cell Longev. (2016) 2016:7239639. 10.1155/2016/7239639

Source: PubMed

3
Se inscrever